Olmesartan Medoxomil Jubilant Pharmaceuticals

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomil Jubilant Pharmaceuticals, is an Angiotensin II receptor blocker (ARB) presented as a tablet for oral use. It is used to manage high blood pressure in adult patients. GNH USA supplies Olmesartan Medoxomil Jubilant Pharmaceuticals as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmesartan Medoxomil Jubilant Pharmaceuticals as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan medoxil is an ARB that lowers blood pressure by blocking the effects of angiotensin II.

- Hypertension: Helps reduce systolic and diastolic blood pressure in adults. - Heart failure: Contributes to improved cardiac output and symptom control when used with other heart‑failure therapies. - Diabetic nephropathy: Slows progression of kidney damage associated with type 2 diabetes. - Post‑myocardial infarction: Assists in blood‑pressure control to lower the risk of further cardiovascular events. - Stroke prevention: Aids in long‑term blood‑pressure management to reduce recurrent stroke risk.

Olmesartan medoxil may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness or light‑headed when standing. - Headache. - Fatigue. - Nasal congestion. - Diarrhoea. - Mild elevation of blood‑urea nitrogen.

Serious or Rare Side Effects: - Angio‑edema involving the face, lips or tongue. - Severe hypotension, especially after dose initiation. - Acute kidney injury or worsening renal function. - Hyperkalemia. - Liver enzyme abnormalities. - Allergic skin reactions such as rash or urticaria.

Olmesartan medoxil should be used with caution in specific clinical situations and according to professional guidance.

- Pregnancy: Contra‑indicated in the second and third trimesters due to fetal toxicity risk. - Breastfeeding: Not recommended as it may pass into breast milk. - Renal impairment: Dose adjustment may be required; monitor kidney function. - Electrolyte balance: Monitor serum potassium, especially with potassium‑sparing diuretics. - Drug‑induced hypotension: Advise patients to rise slowly from sitting or lying positions. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan medoxil has several potential drug‑interactions that may require monitoring or avoidance.

Major Interactions (Avoid): - Concomitant use with  N‑  N‑          -   - 

Moderate